TriLink Biotechnologies Introduces CleanCap M6 Analog
The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.
TriLink Biotechnologies launched its new cap analog, CleanCap M6, on May 9, 2023, which is expected to help developers and researchers maximize the impact of their messenger RNA (mRNA) therapeutics and vaccines while reducing overall manufacturing costs, according to a company press release. The introduction of CleanCap M6 technology is intended to improve mRNA potency with the highest protein expression of any CleanCap analog to date.
“TriLink’s portfolio of CleanCap mRNA capping technology is expected to be the new go-to capping method in the very near future—it is the future,” said Kate Broderick PhD, chief innovation officer at Maravai LifeSciences, in a press release. “What excites me most about this novel analog is its ability to make mRNA an even more powerful therapeutic than we have seen previously.”
The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.
“mRNA is clearly an emerging therapeutic modality where mRNA vaccines and therapeutics are expanding rapidly,” said Drew Burch, EVP of TriLink’s Nucleic Acid Products division, in a press release. “CleanCap M6, and the entire CleanCap portfolio, joins a strong roster of synthesized nucleic acids, NTPs, and more that we expect to continue to grow.”
Source: TriLink Biotechnologies
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
